Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Prime Medicine (NASDAQ:PRME) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

Several other analysts have also issued reports on PRME. Wall Street Zen lowered Prime Medicine from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prime Medicine in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Prime Medicine Stock Performance

Shares of PRME stock opened at $4.12 on Monday. The company has a market cap of $743.70 million, a P/E ratio of -3.05 and a beta of 2.56. Prime Medicine has a 1 year low of $1.11 and a 1 year high of $6.94. The company’s fifty day simple moving average is $3.81.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.